Alvotech has a new vedolizumab BLA and new marketing partner, and Stelara biosimilars produced equivalent clinical outcomes to the reference product over 6 months of treatment. Alvotech’s Second Application for Vedolizumab Biosimilar and New Marketing Partner Alvotech announced that the FDA has accepted its 351(k) application for a prefilled syringe and autoinjector formulation of vedolizumab. … Continue reading Biosimilar Bytes: Alvotech Biosimilar News and 6-Month Ustekinumab Switching Outcomes